
                         Roanoke Times
                 Copyright (c) 1995, Landmark Communications, Inc.

DATE: TUESDAY, July 13, 1993                   TAG: 9307130227
SECTION: NATIONAL/INTERNATIONAL                    PAGE: A-2   EDITION: METRO 
SOURCE: 
DATELINE: WASHINGTON                                LENGTH: Short

2 MORE PATIENTS ILL IN HEPATITIS-DRUG TEST

Two more patients who received an experimental drug for chronic hepatitis B have become so ill that they were referred to the University of Virginia Hospital to await liver transplants, an NIH spokeswoman said Monday.

That brings to five the number of patients who have experienced severe adverse effects in connection with a 15-person drug study conducted by the National Institutes of Health. Two participants died after liver transplants.

The drug, fialuridine, manufactured by Eli Lilly & Co., was considered a promising treatment for chronic hepatitis B, a viral disease of the liver that has no other satisfactory treatment. - The Washington Post

by CNB